CellCentric, Inc News Releases

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

Sun, 07 Dec 2025 08:00:00 -0500

- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients -- Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-BCMA exposed patients -Cambridge, United Kingdom and Boston,...

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

Mon, 03 Nov 2025 09:00:00 -0500

- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population -- The Company will host a live investor event on December 7, at 8:00 p.m. ET in Orlando following the poster presentation -Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - November 3, 2025) - CellCentric, a clinical-stage biotechnology...

CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma

Tue, 09 Sep 2025 07:00:00 -0400

Dose optimization will inform dose for registration studiesInitial data expected by year end 2025Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 9, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced completion of patient enrollment in the randomized dose optimization portion of its Phase 1/2 clinical trial evaluating inobrodib in...

CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma

Wed, 03 Sep 2025 07:00:00 -0400

New cohorts initiated in ongoing Phase 1/2 clinical trial to evaluate inobrodib in combination with teclistamab or elranatamab for the treatment of relapsed/refractory multiple myelomaInitial safety data expected by year endCambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 3, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced that it...

CellCentric to Participate in Upcoming Investor Conferences

Tue, 05 Aug 2025 09:28:00 -0400

Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) - CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences.These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering...